Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients

Abroad (travel likely)Recruiting

Conditions

Newly Diagnosed Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Lingzhi Yan, Suzhou, Jiangsu, China
Contact: Study coordinator (Lingzhi Yan) · hongcikjc@163.com · 0512-65698333

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Newly Diagnosed · High Risk · MRD

Abroad (travel likely)RecruitingPHASE4

Suzhou, China

Horizon Two: HR NDMM (MMRC-100)

High Risk Newly Diagnosed Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Atlanta, United States · Chicago, United States

A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

Multiple Myeloma · AL Amyloidosis

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma · Cancer

Abroad (travel likely)RecruitingPHASE2

Chapel Hill, United States · Charlotte, United States